Sim&Cure Secures €3 Million Funding to Expand Neurovascular Aneurysm Treatment Solutions

Recently, VCBeat (WeChat official account: vcbeat) learned that medical technology company Sim＆Cure has completed a €3 million financing round. The company will use the funds to expand its business scope in the treatment of cerebral aneurysms. This round was led by Elaia, with participation from IT Translation.

Sim＆Cure was founded in 2014 and is headquartered in Montpellier, France. Co-founded by Mathieu Sanchez (former R&D engineer at Philips Healthcare, PhD in Biomechanics) and Vincent Costalat (MD, Head of the Department of Neuroradiology at Montpellier University Hospital), the company is a medical technology firm dedicated to improving neurovascular treatment solutions for aneurysms. Its medical software has been deployed in 250 hospitals, treating over 1,500 patients.

Cerebral aneurysms are a type of arterial malformation, affecting 1 in every 50 people worldwide. In other words, a vessel rupture occurs every 18 minutes, leading to stroke. Vessel rupture is the third leading cause of stroke, and the proper treatment of cerebral aneurysms is a major concern for health authorities. Currently, the primary treatment for cerebral aneurysms relies on neurovascular prostheses (endovascular devices). Statistics show that 92% of patients receive oversized prostheses, which can compromise treatment efficacy.

Sim&Size, developed by Sim＆Cure, provides vascular prostheses in the most appropriate sizes based on each patient’s unique anatomy and clinical condition, thereby reducing surgeons’ operative time, lowering surgical risks for patients, and improving treatment outcomes.

Mathieu Sanchez, CEO of Sim&Cure, stated, “Over the past two years, studies have demonstrated that Sim&Size can significantly improve treatment outcomes for patients in Europe. Our goal in the coming years is to introduce Sim&Size to the U.S. market and increase its adoption among American physicians. We believe Sim&Size will become the standard of care for treating cerebral aneurysms. We also plan to embark on a new round of research and development to further enhance patient outcomes by providing surgeons with more reliable preoperative information.”

Elaia partner Samantha Jerusalmy added, “Sim＆Cure is in an era of rapid innovation and has launched a blockbuster product into the market. Sim＆Cure saves patients’ lives by providing personalized treatment plans, and we are delighted to participate in this investment.”

Elaia, founded in 2002, is an independent venture capital firm. The company focuses on investing in areas such as the digital economy and deep tech. Elaia manages over €350 million in assets and has two active investment funds: the Elaia Delta Fund and PSL. The Elaia Delta Fund is an early-stage venture fund dedicated to participating in seed or Series A financing rounds for digital technology companies. The PSL Innovation Fund is a fund committed to pre-seed or seed financing rounds for deep-tech startups affiliated with PSL research laboratories.

IT Translation is a venture capital firm focused on investing in the digital technology sector. The company has invested in 25 startups over four years.

(Compiled by Song Chenchen)